NCT06049147View on ClinicalTrials.gov

Study to Assess the Safety and Tolerability of MBF-015 in Healthy Young Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

July 7, 2021

Primary Completion Date

August 24, 2023

Study Completion Date

August 24, 2023

Conditions
Safety and Pharmacokinetic
Interventions
DRUG

MBF-015 4 mg oral capsule

MBF-015 oral capsules Histone deacetylase inhibitor

DRUG

MBF-015 16 mg oral capsule

MBF-015 oral capsules Histone deacetylase inhibitor

DRUG

Placebo

Hard gelatin capsules filled with cellulose microcrystalline

Trial Locations (1)

08041

CIM-Sant Pau Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Barcelona

Sponsors

Lead Sponsor

Medibiofarma S.L.
All Listed Sponsors
lead

Medibiofarma S.L.

INDUSTRY

NCT06049147 - Study to Assess the Safety and Tolerability of MBF-015 in Healthy Young Volunteers | Biotech Hunter | Biotech Hunter